8-K: Inhibrx Unveils Strong Clinical Data, Strategic Milestones

Inhibrx Biosciences, Inc. updated investors on its corporate strategy and clinical pipeline, showcasing positive data for ozekibart in chondrosarcoma and INBRX-106 in oncology, alongside key financial highlights.

Summary

• Inhibrx Biosciences, Inc. (the Company) posted an updated corporate presentation on February 23, 2026, outlining its business strategy and clinical pipeline.
• The Company's mission is to discover and develop effective biologic treatments for people with life-threatening conditions.
• As of September 30, 2025, the Company reported $153.1 million in cash and cash equivalents.
• Common stock outstanding was 14.5 million, with 19.6 million fully diluted outstanding, including employee and BOD option reserves, pre-funded warrants, and warrants.
• Ozekibart (INBRX-109) demonstrated unprecedented data in chondrosarcoma, meeting its primary endpoint with a 52% reduction in the risk of disease progression or death (HR=0.479; P<0.0001).
• Median Progression-Free Survival (PFS) for ozekibart in chondrosarcoma more than doubled to 5.52 months compared to 2.66 months for placebo.
• The disease control rate for ozekibart in chondrosarcoma was 54% versus 27.5% for placebo.
• INBRX-106, a hexavalent OX40 agonist, showed robust single-agent biological activity and promising combination efficacy with pembrolizumab in Phase 1 trials for PD-L1+ CPI-R/R NSCLC and HNSCC.
• INBRX-106 in combination with FOLFIRI for colorectal adenocarcinoma showed a 92% disease control rate and 23% objective response rate in evaluable patients.
• INBRX-106 in combination with IRI/TMZ for Ewing sarcoma showed a 92% disease control rate and 64% objective response rate in evaluable patients.
• Ozekibart also exhibited anti-tumor activity in Glioblastoma Multiforme (GBM) models as monotherapy and in combination with temozolomide (TMZ).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by strong clinical data for both ozekibart and INBRX-106, particularly the 'unprecedented' chondrosarcoma results and promising early oncology combination data, despite a strategic transaction pause.

Positives

• Ozekibart (INBRX-109) achieved its primary endpoint in chondrosarcoma with a 52% reduction in disease progression or death (HR=0.479; P<0.0001), described as 'unprecedented data'.
• Median PFS for ozekibart in chondrosarcoma more than doubled to 5.52 months versus 2.66 months for placebo.
• Ozekibart's benefit in chondrosarcoma was consistent across all pre-specified subgroups.
• INBRX-106 demonstrated robust single-agent biological activity, inducing potent, dose-dependent expansion of CD4+ and CD8+ memory T cells.
• INBRX-106 with pembrolizumab showed durable complete responses in HNSCC patients and ongoing responses for over a year in NSCLC patients.
• INBRX-106 in combination with FOLFIRI for colorectal adenocarcinoma achieved a 92% disease control rate and 23% objective response rate in evaluable patients.
• INBRX-106 in combination with IRI/TMZ for Ewing sarcoma achieved a 92% disease control rate and 64% objective response rate in evaluable patients.
• Ozekibart showed anti-tumor activity and enhanced survival in GBM models, both as monotherapy and in combination with TMZ.
• The Company maintains a strong cash position of $153.1 million as of September 30, 2025.
• High internal ownership is aligned with investor interests, focusing on maximizing net shareholder value.

Negatives

• First-generation bivalent OX40 therapeutics showed underwhelming activity due to insufficient T-cell activation and suboptimal target engagement, highlighting challenges in this therapeutic class.
• Ozekibart treatment in chondrosarcoma led to a higher incidence of Grade 3 adverse events (39.0% vs 25.4% for placebo) and serious adverse events (27.9% vs 17.9% for placebo).
• One death was reported as treatment-related for ozekibart (0.7%) compared to zero for placebo in the chondrosarcoma trial.

Risks

• Forward-looking statements involve substantial known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different.
• The Company may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and undue reliance should not be placed on them.
• Investigational product candidates discussed have not been approved or licensed by the U.S. Food and Drug Administration or any other regulatory authority and are not commercially available.
• Projections, assumptions, and estimates of the Company's future performance and market performance are necessarily subject to a high degree of uncertainty and risk.
• Ozekibart treatment showed higher rates of Grade 3 adverse events, serious adverse events, and hepatic adverse events compared to placebo in the chondrosarcoma study.

Future Outlook

Inhibrx anticipates significant shareholder value creation from anticipated 2026 milestones for its ozekibart and INBRX-106 programs. This includes a Biologics License Application (BLA) submission for ozekibart in chondrosarcoma in 2H 2026 with potential approval in 2026, and interim and PFS data readouts for INBRX-106 in HNSCC in 1H and 2H 2026, respectively, with Phase 3 activation planned for Q3 2026. The company also plans to expand INBRX-106 development into NSCLC and other PD-1 sensitive indications, aiming for oncology market leadership.

Management Comments

• Our mission: To discover & develop effective biologic treatments for people with life-threatening conditions.
• Our high internal ownership is aligned with our investors interests.
• Anticipated 2026 milestones for each program could potentially create significant shareholder value.

Industry Context

StockSavvy.ai notes that Inhibrx is strategically positioning its oncology pipeline, particularly with INBRX-106, to address the limitations of first-generation OX40 agonists and enhance the efficacy of established PD-1 blockade therapies like pembrolizumab. The focus on high PD-L1 HNSCC for INBRX-106's registrational study aims to demonstrate clear additive benefit in a competitive immunotherapy landscape, while ozekibart targets rare cancers like chondrosarcoma and Ewing sarcoma, where unmet needs are high and current standard-of-care treatments offer limited efficacy.

Comparison to Industry Standards

• For ozekibart in chondrosarcoma, the median PFS of 5.52 months significantly surpasses the 2.66 months for placebo, representing a 52% reduction in progression risk, which is described as 'unprecedented data' in this indication.
• For INBRX-106 in 1L HNSCC, the randomized add-on study design (INBRX-106 + Pembro vs. Pembro) aims to demonstrate superiority over pembrolizumab monotherapy, which achieved an ORR of 23.3% in the PD-L1 CPS > 20 HNSCC population in Keynote 48.
• For INBRX-109 in 3-4L colorectal adenocarcinoma, the 92% disease control rate and 23% objective response rate compare favorably to current standard-of-care treatments like Lonsurf + Bevacizumab (6.1% ORR, 5.6 months PFS), Regorafenib (1.0% ORR, 1.9 months PFS), and Fruquintinib (1.5% ORR, 3.7 months PFS).
• For INBRX-109 in 2-3L Ewing sarcoma, the 92% disease control rate and 64% objective response rate are substantially higher than reported ORRs for Irinotecan + Temozolomide (~15-30%) and HD Ifosfamide (~20-25%), and PFS of 3-4 months and 5.7 months respectively.

Stakeholder Impact

• Shareholders: Potential for significant value creation from anticipated 2026 milestones, especially if INBRX-106 readouts are positive and ozekibart gains approval. The pause on the ozekibart transaction could delay immediate monetization but aims to maximize net shareholder value.
• Patients: Promising new treatment options for life-threatening conditions like chondrosarcoma, Ewing sarcoma, colorectal adenocarcinoma, and HNSCC, where current therapies have limited efficacy.
• Employees: Continued focus on discovery and development, potentially leading to growth and stability within the company.

Next Steps

• Update on Phase 1 Ewing Sarcoma safety and efficacy data for Ozekibart in 1H 2026.
• Interim ORR data for randomized, first-line HNSCC (INBRX-106 vs. INBRX-106/Pembro) in 1H 2026.
• BLA submission for ozekibart for the treatment of metastatic or unresectable chondrosarcoma in 2H 2026.
• PFS data for Phase 1/2 late-line CRC cohort for Ozekibart in 2H 2026.
• PFS data for randomized, first-line HNSCC (INBRX-106 vs. INBRX-106/Pembro) in 2H 2026.
• Potential approval of ozekibart for the treatment of metastatic or unresectable chondrosarcoma in 2026.
• Potential meeting with FDA to discuss accelerated approval for Ewing sarcoma and/or fourth-line CRC for Ozekibart in 2026.
• Phase 3 activation for INBRX-106 in 1L HNSCC in Q3 2026.
• Pursue significant market value in NSCLC through three studies: pembro+106 in 1L TPS > 50% (chemo-free); 1L combination with pembro/chemo (all comers); and peri-operative.
• Expand INBRX-106 to +10-20 additional PD-1 effective indications.

Key Dates

Recommendation

The filing presents exceptionally strong clinical data for ozekibart in chondrosarcoma, demonstrating unprecedented efficacy with a significant reduction in disease progression and a doubling of median PFS. Furthermore, INBRX-106 shows highly promising early-stage data in multiple difficult-to-treat cancers, with a clear development path towards registrational studies. The company's solid cash position and strategic focus on maximizing shareholder value, despite pausing a potential ozekibart transaction for optimal timing, underscore a robust outlook. These positive clinical advancements and strategic clarity make Inhibrx a compelling 'strong buy' for investors seeking exposure to innovative oncology biotherapeutics.

Keywords

Inhibrx Biosciences, INBX, biotechnology, oncology, immunotherapy, ozekibart, INBRX-109, chondrosarcoma, Ewing sarcoma, colorectal adenocarcinoma, glioblastoma, INBRX-106, OX40 agonist, PD-1 blockade, cancer treatment, clinical trials, SEC filing, corporate presentation, drug development, biologics